Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders
Source: Acta Psychiatrica Scandinavica, Volume 113, Supplement 430, May 2006 , pp. 29-39(11)
Abstract:Kopala L, Smith G, Malla A, Williams R, Love L, Talling D, Balshaw R. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Acta Psychiatr Scand 2006: 113 (Suppl. 430): 29–39. © 2006 Blackwell Munksgaard. Objective:
To determine how the use of the newer, so called atypical antipsychotic medications, effects the pharmacoeconomic treatment burden of schizophrenia and related conditions and to provide a clear comparison of the costs and risks associated with these atypical drugs. Method:
In this 2-year, open-label, prospective study, resource utilization (RU) data were collected on 160 patients with these conditions. A comparison between risks and costs was performed by combining the generalized CNOMSS data on both economic factors and risk assessments. Results:
The main findings of the study were that the total adjusted 1- and 2-year costs were lowest for quetiapine. Drug acquisition costs were lowest for risperidone for both the 1- and 2-year cohorts. Clozapine use was predictably associated with the highest overall and medication costs at both 1 and 2 years. Conclusion:
Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine.
Document Type: Research Article
Publication date: 2006-05-01